These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 37517522)
1. Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial. Coyle V; Forde C; McAuley DF; Wilson RH; Clarke M; Plummer R; Grayson M; McDowell C; Agus A; Doran A; Thomas AL; Barnes RA; Adams R; Chau I; Storey D; McMullan R; Clin Microbiol Infect; 2024 Jan; 30(1):92-99. PubMed ID: 37517522 [TBL] [Abstract][Full Text] [Related]
2. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT. Coyle V; Forde C; Adams R; Agus A; Barnes R; Chau I; Clarke M; Doran A; Grayson M; McAuley D; McDowell C; Phair G; Plummer R; Storey D; Thomas A; Wilson R; McMullan R Health Technol Assess; 2024 Mar; 28(14):1-101. PubMed ID: 38512064 [TBL] [Abstract][Full Text] [Related]
3. Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Forde C; McMullan R; Clarke M; Wilson RH; Plummer R; Grayson M; McDowell C; Agus A; Doran A; McAuley DF; Thomas AL; Barnes RA; Adams R; Chau I; Coyle V Trials; 2020 May; 21(1):431. PubMed ID: 32460818 [TBL] [Abstract][Full Text] [Related]
4. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT. Scarborough M; Li HK; Rombach I; Zambellas R; Walker AS; McNally M; Atkins B; Kümin M; Lipsky BA; Hughes H; Bose D; Warren S; Mack D; Folb J; Moore E; Jenkins N; Hopkins S; Seaton RA; Hemsley C; Sandoe J; Aggarwal I; Ellis S; Sutherland R; Geue C; McMeekin N; Scarborough C; Paul J; Cooke G; Bostock J; Khatamzas E; Wong N; Brent A; Lomas J; Matthews P; Wangrangsimakul T; Gundle R; Rogers M; Taylor A; Thwaites GE; Bejon P Health Technol Assess; 2019 Aug; 23(38):1-92. PubMed ID: 31373271 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial. Keij FM; Kornelisse RF; Hartwig NG; van der Sluijs-Bens J; van Beek RHT; van Driel A; van Rooij LGM; van Dalen-Vink I; Driessen GJA; Kenter S; von Lindern JS; Eijkemans M; Stam-Stigter GM; Qi H; van den Berg MM; Baartmans MGA; van der Meer-Kappelle LH; Meijssen CB; Norbruis OF; Heidema J; van Rossem MC; den Butter PCP; Allegaert K; Reiss IKM; Tramper-Stranders GA Lancet Child Adolesc Health; 2022 Nov; 6(11):799-809. PubMed ID: 36088952 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
7. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial. Hill LF; Clements MN; Turner MA; Donà D; Lutsar I; Jacqz-Aigrain E; Heath PT; Roilides E; Rawcliffe L; Alonso-Diaz C; Baraldi E; Dotta A; Ilmoja ML; Mahaveer A; Metsvaht T; Mitsiakos G; Papaevangelou V; Sarafidis K; Walker AS; Sharland M; Lancet Child Adolesc Health; 2022 Jan; 6(1):49-59. PubMed ID: 34843669 [TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy of a 7-day versus a 14-day course of intravenous antibiotics in the treatment of uncomplicated neonatal bacterial sepsis: study protocol of a randomized controlled non-inferiority trial. Dutta S; Nangia S; Jajoo M; Gathwala G; Nesargi S; Sundaram M; Kumar P; Saili A; Kumar D; Dalal P; Suman Rao PN; Shanmugam R; Ray P; Randhawa VS; Saigal K; Sharma M; Nagaraj S; Radhakrishnan D Trials; 2021 Nov; 22(1):859. PubMed ID: 34844643 [TBL] [Abstract][Full Text] [Related]
9. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST). Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334 [TBL] [Abstract][Full Text] [Related]
10. Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials. Lemaignen A; Bernard L; Tattevin P; Bru JP; Duval X; Hoen B; Brunet-Houdard S; Mainardi JL; Caille A; BMJ Open; 2020 Jul; 10(7):e033540. PubMed ID: 32665381 [TBL] [Abstract][Full Text] [Related]
11. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Stocker M; van Herk W; El Helou S; Dutta S; Fontana MS; Schuerman FABA; van den Tooren-de Groot RK; Wieringa JW; Janota J; van der Meer-Kappelle LH; Moonen R; Sie SD; de Vries E; Donker AE; Zimmerman U; Schlapbach LJ; de Mol AC; Hoffman-Haringsma A; Roy M; Tomaske M; Kornelisse RF; van Gijsel J; Visser EG; Willemsen SP; van Rossum AMC; Lancet; 2017 Aug; 390(10097):871-881. PubMed ID: 28711318 [TBL] [Abstract][Full Text] [Related]
12. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593 [TBL] [Abstract][Full Text] [Related]
13. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Innes HE; Smith DB; O'Reilly SM; Clark PI; Kelly V; Marshall E Br J Cancer; 2003 Jul; 89(1):43-9. PubMed ID: 12838298 [TBL] [Abstract][Full Text] [Related]
14. Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV. Kern WV; Marchetti O; Drgona L; Akan H; Aoun M; Akova M; de Bock R; Paesmans M; Viscoli C; Calandra T J Clin Oncol; 2013 Mar; 31(9):1149-56. PubMed ID: 23358983 [TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial. Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739 [TBL] [Abstract][Full Text] [Related]
16. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC; Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631 [TBL] [Abstract][Full Text] [Related]
17. Very early discharge versus early discharge versus non-early discharge in children with cancer and febrile neutropenia. Loeffen EA; Te Poele EM; Tissing WJ; Boezen HM; de Bont ES Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008382. PubMed ID: 26899263 [TBL] [Abstract][Full Text] [Related]